Note: This page is horribly out of
date.
You can find the current pages for the dm-crypt
project (the Linux kernel part) here:
https://gitlab.com/cryptsetup/cryptsetup/wikis/DMCrypt
and the project page for the command line tool
cryptsetup (with Linux Unified Key
Setup - LUKS) here: https://gitlab.com/cryptsetup/cryptsetup.
Old page:
Device-mapper is a new infrastructure in the Linux 2.6 kernel that provides
a generic way to create virtual layers of block devices that can do different
things on top of real block devices like striping, concatenation, mirroring,
snapshotting, etc... The device-mapper is used by the
LVM2 and
EVMS 2.x tools.
dm-crypt is such a device-mapper target that provides transparent encryption of
block devices using the new Linux 2.6 cryptoapi. The user can basically specify
one of the symmetric ciphers, a key (of any allowed size), an iv generation mode
and then the user can create a new block device in /dev. Writes to this device
will be encrypted and reads decrypted. You can mount your filesystem on it as usual.
But without the key you can't access your data.
It does basically the same as cryptoloop only that it's a much cleaner code and
better suits the need of a block device and has a more flexible configuration
interface. The on-disk format is also compatible. In the future you will be able
to specify other iv generation modes for enhanced security (you'll have to
reencrypt your filesystem though).
I've set up a Wiki.
There's a mailing list at .
If you want to subscribe, use the mailman
web interface or its
archive.
Gmane provides a NNTP interface and also a
web archive
for this mailing list.
There is support for dm-crypt in the latest official kernel
2.6.4
which you can find on kernel.org.
Please use the mirrors for downloads.
There is a HIGHMEM cryptoapi bug in kernels before 2.6.4-rc2, please
upgrade if you were using such a kernel.
The latest version of the native userspace setup tool is cryptsetup 0.1.
Clemens Fruhwirth is maintaining an
enhanced
version of cryptsetup with the LUKS extension that allows you to have an
on-disk block of metadata which is superior to the current mechanism and was
my long term plan anyway but I didn't find the time to implement that yet...
Pharmacology is the vital bridge in drug discovery and development, providing the scientific framework to understand how a potential medicine interacts with the body. By integrating the two core disciplines— pharmacokinetics (PK) pharmacodynamics (PD)
Often described as "what the body does to the drug." It tracks the drug's journey through bsorption into the bloodstream, istribution to tissues, etabolism (often in the liver), and xcretion from the body. Pharmacodynamics (PD):
For example, in the discovery of statins (HMG-CoA reductase inhibitors), pharmacological validation proved that inhibiting this liver enzyme directly lowered LDL cholesterol. Without this proof, investment in chemical synthesis would be gambling, not science.
Hit-to-Lead: Picking the best "hits" and refining their chemistry.
The greatest challenge in the field is the "translation gap." Human biology is vastly more complex than animal models or cell cultures. A drug that works beautifully in a mouse model of Alzheimer’s may fail completely in a human patient.
Pharmacodynamics (PD): What the drug does to the body (potency and efficacy).
A wide TI (e.g., Penicillin: TI > 100) is safe. A narrow TI (e.g., Digoxin for heart failure: TI ~ 2) is dangerous. Pharmacologists generate DRCs for both efficacy and toxicity in at least two animal species (typically rodent and non-rodent) before regulatory filing.
“The right drug, at the right dose, for the right patient” — pharmacology is the science that makes this possible.
The on-disk layouts used by the current 2.6 cryptoloop are supported by dm-crypt.
Cryptoloop also uses cryptoapi so the name of the ciphers are the same. Cryptoloop also
supports ECB and CBC mode. Use <cipher>-ecb and
<cipher>-plain accordingly with dm-crypt. If you didn't
explicitly specify either -ecb or -cbc before you don't need it now, the default plain
IV generation will be used. There will be additional (incompatible, but more secure) possibilites
in the future because the unhashed sector number as IV is too predictible.
You'll need to figure out how your passphrase was turned into a key to use for losetup.
There are several patches floating around doing things differently. But usually cryptsetup
will provide a working solution to recreate the same key from your passphrase.
If you want to migrate from 2.4 cryptoloop please take a look at Clemens Fruhwirth's
Cryptoloop
Migration Guide. He describes the differences between 2.4 and 2.6 cryptoapi (or basically
the bugs in 2.4 cryptoapi...). If you need to cut the key size you can use the -s
option instead of playing with dd.
(BTW: Clemens has a i586 optimized version of the aes and serpent cipher on his page,
about twice as fast as the kernel implementation.)
Why dm-crypt?
Originally it started as a fun project because I wanted to play with the new Linux 2.6 internals.
I got a lot of great help from the device-mapper guys at Sistina (now Redhat). Thank you very
much!
It turned out that this implementation worked great and is very clean compared to the hacked
loop device. The device-mapper core provides much better facilities to stack block devices.
dm-crypt uses mempools to assure we never run into out-of-memory deadlocks when allocating
buffers.
Also the device-mapper configuration interface provides much more flexibility than the losetup
ioctl. And you can create as many devices as you want with any names you want and combine them
with other dm targets. Online device resizing is also possible, e.g. if you use dm-crypt on top
of a logical volume. There might perhaps even be LVM or EVMS support for device encryption
in the future.
Pharmacology is the vital bridge in drug discovery and development, providing the scientific framework to understand how a potential medicine interacts with the body. By integrating the two core disciplines— pharmacokinetics (PK) pharmacodynamics (PD)
Often described as "what the body does to the drug." It tracks the drug's journey through bsorption into the bloodstream, istribution to tissues, etabolism (often in the liver), and xcretion from the body. Pharmacodynamics (PD):
For example, in the discovery of statins (HMG-CoA reductase inhibitors), pharmacological validation proved that inhibiting this liver enzyme directly lowered LDL cholesterol. Without this proof, investment in chemical synthesis would be gambling, not science. pharmacology in drug discovery and development
Hit-to-Lead: Picking the best "hits" and refining their chemistry.
The greatest challenge in the field is the "translation gap." Human biology is vastly more complex than animal models or cell cultures. A drug that works beautifully in a mouse model of Alzheimer’s may fail completely in a human patient. Pharmacology is the vital bridge in drug discovery
Pharmacodynamics (PD): What the drug does to the body (potency and efficacy).
A wide TI (e.g., Penicillin: TI > 100) is safe. A narrow TI (e.g., Digoxin for heart failure: TI ~ 2) is dangerous. Pharmacologists generate DRCs for both efficacy and toxicity in at least two animal species (typically rodent and non-rodent) before regulatory filing. Penicillin: TI >
“The right drug, at the right dose, for the right patient” — pharmacology is the science that makes this possible.
Please contact the mailing list: dm-crypt@saout.de. Or in case there is a problem with the mailing list, me: .